How Do NK Cells Find Cancer Cells? A Patient Guide for Osaka

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

When people first hear about NK cell therapy, a natural question follows: what exactly do these cells do inside the body? Understanding the basic mechanism helps you ask better questions during a consultation. This article explains, in plain language, how natural killer (NK) cells are thought to detect and attack abnormal cells, and what that means for patients, including international patients, who are considering treatment at Grand Green Osaka Umekita Clinic in Osaka.

The short answer

NK cells are a type of lymphocyte that circulates in the blood and can attack cancer cells and virus-infected cells without waiting for instructions from other immune cells. In NK cell therapy, a patient’s own NK cells are obtained from a standard blood draw, activated and expanded at a specialized facility, and returned by intravenous infusion. The aim is to reinforce immune function that may have weakened. This is a self-pay (non-insured) treatment, and whether it is appropriate for you must be decided together with a doctor after an examination.

What NK cells are and where they fit in the immune system

The immune system has many kinds of cells, and they are often described as belonging to two broad groups. Innate immune cells respond quickly and do not need to learn about a specific target beforehand. Adaptive immune cells take longer to respond but become highly specific. NK cells belong to the innate group. Their name, “natural killer,” reflects the fact that they can act on abnormal cells they encounter without prior sensitization.

You can picture NK cells as patrols moving through the bloodstream and tissues. As they move, they check the cells they meet. Healthy cells are generally left alone, while cells that look abnormal can become targets. This role is closely connected to the idea of immune surveillance, the process by which the immune system is thought to find and remove abnormal cells before they grow into something larger.

How NK cells are thought to recognize and attack abnormal cells

Researchers describe NK cell recognition as a balance of signals. Cells carry molecules on their surface that act like identification markers. Some signals tell an NK cell to hold back, and others suggest that something is wrong. When the balance tips toward the second kind, the NK cell can be triggered to act. This is a simplified picture, and the details differ from one tumor type to another, which is one reason a doctor’s individual assessment matters.

Once an NK cell is triggered, it can attack directly. One commonly described mechanism involves molecules such as perforin, which help the NK cell damage the target cell. Because this direct action does not depend on instructions from other immune cells, NK cells are often described as being among the first responders of the immune system.

It is important to keep this explanation in perspective. Laboratory and animal findings do not automatically translate into the same results for every person, and cancer cells can find ways to avoid immune detection. For that reason, how NK cells work in principle should never be read as a promise of what a treatment will achieve for an individual patient.

Why NK cell activity may matter, and why therapy is considered

NK cell activity has been reported to decline with age, with stress, and as a result of cancer itself. When activity is lower, the surveillance function described above may be less effective. NK cell therapy is designed with this in mind. By collecting NK cells, activating and expanding them outside the body, and returning them by infusion, the therapy aims to supply more cells with higher activity.

Because the therapy uses your own cells, the risk of rejection is considered low, and serious side effects have rarely been reported. Even so, temporary reactions such as fever or fatigue may occur, and every treatment carries some uncertainty. The treatment consists of a blood draw and an intravenous infusion and does not require hospitalization, so many patients can continue daily life around their visits, though this should be confirmed for your own situation.

NK cell therapy is not a replacement for standard cancer treatment. It may be considered alongside surgery, chemotherapy, or radiation therapy, but timing and compatibility should be confirmed with your doctors. Your standard treatment team remains central to your care, and the clinic can coordinate with the medical institution that provides it.

Questions to prepare before a consultation in Osaka

A consultation is the place where general science becomes a decision about you. If you are traveling to Japan or living here as a foreign resident, preparing a few questions in advance can make the visit more productive. Consider asking the following.

• Is NK cell therapy suitable for my diagnosis, stage, and current treatment plan?
• How would it fit with the surgery, chemotherapy, or radiation therapy I am receiving or have received?
• What are the expected costs, number of sessions, and overall schedule, and what is not included?
• What side effects or risks could occur, and how will they be monitored and handled?
• What are the limits of this therapy, and what outcomes can reasonably be expected or not expected?
• Can my own doctor be contacted so that information is shared about my care?

It also helps to bring your medical records, recent test results, and a list of your current medications, ideally in English or with translations. Grand Green Osaka Umekita Clinic, located in the Umeda area, provides information pages in multiple languages for foreign patients, which can help you review the basics before your visit.

How the therapy is regulated in Japan

In Japan, cell therapies of this kind are provided under the Act on the Safety of Regenerative Medicine. Under this framework, a provision plan is reviewed by a certified committee and submitted to the Ministry of Health, Labour and Welfare, and cells are processed at licensed facilities. The treatment is self-pay: it is not covered by public health insurance, and costs are paid by the patient. Fees, risks, side effects, and eligibility should all be confirmed directly with a doctor and on the clinic’s official pages before you decide.

A regulatory framework describes how a treatment must be managed. It does not mean that a therapy will work for every patient. Keeping that distinction in mind will help you evaluate any cell therapy realistically.

Summary

NK cells are innate immune cells that patrol the body and can attack abnormal cells directly. NK cell therapy aims to return a larger number of more active, expanded NK cells that come from your own blood. The mechanism is well described in general terms, but individual outcomes vary, and the therapy is considered alongside, not instead of, standard cancer treatment. If you are thinking about NK cell therapy in Osaka, use the questions above to prepare, and discuss your own situation, costs, and risks with a doctor at Grand Green Osaka Umekita Clinic.

1. 1Blood drawYour own cells
2. 2Activate and expandAt a licensed facility
3. 3IV infusionNo hospital stay
4. 4Doctor follow-upConfirm risks and fees

Conceptual overview. Self-pay treatment; ask a doctor about suitability

References

• PubMed: TGF-β-activated NK-92 cell therapy for esophageal squamous cell carcinoma. (2025)
• PubMed: Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer. (2020)
• PubMed: Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet. (2020)
• PubMed: Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. (2005)
• PubMed: Recent advancements and persisting challenges in the evolution of next generation car t cell therapy for solid malignancies: a comprehensive review. (2026)
• PMC: Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. (2014)
• PMC: Advances in natural killer cell immunotherapy for hematologic malignancies. (2026)
• PMC: Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells. (2018)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.